Skip to main content

Cancer Research

Roswell Park Cancer Institute Collaboration with CHS

Bhoomi Mehrotra, MD and Mitchell Chorost, MD

December 2019

bhoomi mehrotra with patient

Catholic Health Systems (CHS) has strengthened its commitment to providing outstanding cancer care for Long Islanders by becoming a member of the newly launched Roswell Park Care Network. One of New York’s premier cancer centers, Roswell Park is nationally recognized as a leader in this field of medicine. In a highly selective process, the Buffalo-based comprehensive cancer center is now partnering with CHS to expand its research network into the downstate region. This agreement provides a collaboration between CHS and Roswell Park for research participation in Roswell Park’s proprietary clinical trials as well those associated with the NCI cooperative research group, Alliance for Clinical Trials in Oncology.
“The field of oncology has made major strides in the past three to five years, based upon novel research. All of those advances have happened by individuals participating in clinical trials,” commented CHS’s Chair of Oncology Bhoomi Mehrotra, MD. “Our partnership with Roswell will give cancer patients in our region access to those innovations.”

“Having completed my surgical oncology fellowship at Roswell Park, I can attest to the expertise of their oncology researchers and their commitment to cancer patients to provide optimal care. The research
staff of St Francis Hospital is looking forward to building upon this relationship and providing opportunities for participation in a clinical trials for our patients. Through research, we hope to improve the care
that we deliver” stated Mitchell Chorost, MD, Chairman of St. Francis Hospital's IRB. In this exclusive partnership for the region, CHS and Roswell Park are launching what is expected to be an exciting collaboration. The new clinical trials will initially be conducted at St. Francis, augmenting currently available studies and innovative therapies offered to Long Islanders. Eventually, these programs will be implemented across the health system, helping to ease the burden of cancer for communities in Nassau, Suffolk and beyond.


   Title of Study                                                                       Principal Investigator

BOSTON TRIAL: A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib, and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Dilip Patel, MD

INSIGHT-MM: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients

Dilip Patel, MD

informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Dilip Patel, MD

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Dilip Patel, MD

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles

Dilip Patel, MD